The U.S. District Court for the Northern District of Texas recently released a joint status report in the case Outsourcing Facilities Association v. U.S. Food and Drug Administration (Case No. 4:24-cv-00953-P). This report, filed on November 21, 2024, outlines ongoing...
The FDA’s recent decision to remove tirzepatide from its shortage list has triggered a legal battle with significant implications for medical spas and compounders. In response to a lawsuit filed by the Outsourcing Facilities Association (OFA) and North American Custom...
The recent case involving Rebecca Fadanelli, owner of Skin Beaute Med Spa, who was arrested on November 1, 2024, on charges of illegal medical practices, is a stark reminder of the importance of integrity and compliance within the med spa industry. While this...
In a surprising turn of events, the U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient in Eli Lilly’s diabetes therapy Mounjaro and weight loss therapy Zepbound, from its drug shortage list. This...
The pharmaceutical landscape is once again at the center of a legal battle. This time, the battle involves the popular drug tirzepatide, manufactured by Eli Lilly under the brand name Mounjaro. Compounders, the small but crucial segment of the pharmaceutical world,...
Recent developments regarding weight loss drugs and the FDA’s policies on compounding pharmacies have sparked significant changes in the healthcare and wellness sectors. With the FDA announcing that Eli Lilly’s popular weight loss drug, Tirzepatide, is no longer...
